Toward a Personalized ‘Fountain of Youth’ in Future

Juan Ding*
Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford St., Boston, MA 02114, USA

For thousands of years, humans have been searching for the fountain of youth. Today, we are living an average lifespan of almost 80 years. As more and more people are becoming old, the studies of aging and age-related diseases are on the rise. Accumulated evidence indicates that it is no longer impossible to extend lifespan and/or delay aging and the onset of age-related diseases. For example, calorie restriction has been shown to increase lifespan in a wide range of organisms including monkeys [1]. Moreover, genes have been discovered to be associated with the regulation of aging, e.g., sirt1, a gene conserved across species, has been found to be an important regulator of longevity in mammals [2]. There are now even drugs that some people believe to be anti-aging, for example, resveratrol, a natural phenol originally extracted from grape skin and has shown anticancer, anti-inflammation, anti-diabetes and beneficial cardiovascular effects in rodent studies. So far the success is seen only in laboratory animals. The question remains whether these regimes and drugs are able to confer increased longevity and healthier aging in humans. And if so, will every individual benefit from them? It is well known that humans have much larger diversity and individuality in their genetic makeup compared to model organisms used in research laboratories. A miracle drug for C57BL6 mice may very well be useless for humans, or at least to some of us. Even well-developed drugs can be metabolized differently with different cytochrome P450 genes hence for humans, or at least to some of us. Even well-developed drugs can be metabolized differently with different cytochrome P450 genes hence affecting their efficacies. The study of pharmacogenomics will help to identify personalized medicine. In this regard, will pharmacogenomics help us to learn more about personalized aging and personalized regime/drug to combat aging?

Interestingly, studies are already showing that genetic polymorphisms of the sirt1 gene are associated with aging [3], overweight [4], cholesterol metabolism and coronary artery calcification [5], and may affect diabetes risk with prenatal exposure to famine [6]. These data suggest that indeed different people may react differently to an anti-aging pharmacological intervention. There will be a lot more studies needed to answer the question fully. In order to achieve this, more research needs to be done.

The most efficient way to share data is to publish through an open access mechanism. Many of us have been through this scenario: you find the very article you need and click on the full text link, but you are asked for a subscriber’s ID and password or pay a ridiculous amount of money. You go through all the digital libraries that your institute has access to and still of no avail. In the final frustration you just give up. Think about the information lost because of this. Readers will not get to read the papers, and the authors will not get acknowledged for their work. With open access, everyone, researchers or lay public, can download and read papers whenever and wherever they want, free of charge, even from the comfort of their home. The Journal of Pharmacogenomics & Pharmacoproteomics not only is open access, so that your work will be appreciated and cited in a much more efficient manner, it also has many other special features such as digital book, audio version-enhanced feature of website, language translation, and even social networking including Facebook, Twitter, LinkedIn, RSS Feeds etc. This way, you and your work stay connected with professionals and friends 24/7. And for the personalized anti-aging regime? We may get there faster.

References

*Corresponding author: Juan Ding, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 20 Staniford St., Boston, MA 02114, USA, Tel: 617-912-0288; E-mail: juan.ding@schepens.harvard.edu

Received January 17, 2012; Accepted January 19, 2012; Published January 23, 2012


Copyright: © 2012 Ding J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.